Current Report Filing (8-k)

false 0001578845 0001578845 2019-11-05 2019-11-05 0001578845 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2019-11-05 2019-11-05 0001578845 agn:FloatingRateNotesDue2020Member 2019-11-05 2019-11-05 0001578845 agn:M0.500NotesDue2021Member 2019-11-05 2019-11-05 0001578845 agn:M1.500NotesDue2023Member 2019-11-05 2019-11-05 0001578845 agn:M1.250NotesDue2024Member 2019-11-05 2019-11-05 0001578845 agn:M2.625NotesDue2028Member 2019-11-05 2019-11-05 0001578845 agn:M2.125NotesDue2029Member 2019-11-05 2019-11-05

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): Nov ember 5, 2019 (November 5, 2019)

 

ALLERGAN PLC

(Exact Name of Registrant as Specified in Charter)

 

Ireland		001-36867		98-1114402
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Clonshaugh Business and Technology Park

Coolock, Dublin, D17 E400, Ireland

(Address of Principal Executive Offices)

[phone]

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Share, par value $0.0001 per share		AGN		New York Stock Exchange
Floating rate notes due 2020		AGN20A		New York Stock Exchange
0.500% notes due 2021		AGN21		New York Stock Exchange
1.500% notes due 2023		AGN23A		New York Stock Exchange
1.250% notes due 2024		AGN24A		New York Stock Exchange
2.625% notes due 2028		AGN28		New York Stock Exchange
2.125% notes due 2029		AGN29		New York Stock Exchange

 

 

---

Item 2.02

Results of Operations and Financial Condition.

On November 5, 2019, Allergan plc (the “Company”) posted an investor FAQ entitled “Third Quarter 2019 Financial Results – Frequently Asked Questions” (the “Investor FAQ”) to the investor relations section of its website. The Investor FAQ is related to the Company’s earnings release for the quarter ended September 30, 2019. A copy of the Investor FAQ is attached hereto as an exhibit 99.1 and incorporated herein by reference.

The information in this report (including the exhibit) is furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit				Description of Exhibit
	Exhibit 99.1			Investor FAQ
	Exhibit 104			Cover Page Interactive Data File (embedded within the Inline XBRL Document)

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 5, 2019				Allergan plc
				By:		/s/ A. Robert D. Bailey
						A. Robert D. Bailey
						EVP and Chief Legal Officer and Corporate Secretary